Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis.
Research article published in The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2019)
Abstract
INTRODUCTION: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide with a prevalence rate of approximately 6%. Although most cases of PPH have no identifiable risk factors, the incidence of PPH has been associated to the thromboprophylaxis in pregnancy with low molecular weight heparin (LMWH). Thus, the aim of the study is to evaluate the risk of PPH in cases of pregnant women exposed to LMWH. MATERIALS AND METHODS: Electronic research was performed in OVID, Scopus, ClinicalTrials.gov, MEDLINE, the PROSPERO International Prospective Register of Systematic Reviews, EMBASE, and the Cochrane Central Register of Controlled Trials through April 2016. We included randomized controlled trials, cohort and case-control studies of women who underwent thromboprophylaxis with LMWH during pregnancy compared to a control group (either placebo or no treatment). The primary outcome was the incidence of PPH. The summary measures were reported as relative risk (RR) or as mean differences (MD) with 95% confidence interval (CI). RESULTS: Eight studies including 22,162 women were analyzed. Of the 22,162 women, 1320 (6%) were administered LMWH, 20,842 (94%) women formed the nonexposed group (control group). Women treated with LMWH had a higher risk of PPH (RR 1.45, 95%CI 1.02-2.05) compared to controls; there was no difference in mean of blood loss at delivery (MD -32.90, 95%CI 68.72-2.93) and in risk of blood transfusion at delivery (RR 1.24, 95%CI 0.62-2.51), respectively. CONCLUSIONS: Women who receive LMWH during pregnancy have a significantly higher risk of developing PPH. Women who receive LMWH during pregnancy have neither significantly higher mean blood loss at delivery nor higher risk of blood transfusion.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis.
Warum dies für die Hirudotherapie relevant ist
Diese systematische Übersichtsarbeit und Metaanalyse von acht Studien und 22.162 Frauen ergab, dass die Thromboseprophylaxe mit niedermolekularem Heparin während der Schwangerschaft mit einem signifikant höheren Risiko für postpartale Blutungen verbunden war (RR 1,45, 95% CI 1,02–2,05), jedoch ohne signifikanten Unterschied beim mittleren Blutverlust oder Transfusionsrisiko. Ihre Relevanz für die Hirudotherapie ist indirekt und veranschaulicht die blutungsbezogenen Kompromisse, die systemischen Antikoagulanzien wie heparin innewohnen, im Gegensatz zur lokalisierten, selbstbegrenzenden Blutung bei der Blutegelanwendung. Der Vorbehalt ist erheblich: Diese Metaanalyse betrifft systemisches LMWH bei geburtshilflichen Patientinnen und hat keinen Zusammenhang mit medizinischen Blutegeln oder dem Blutegel-Sekretom, sodass sie nur einen allgemeinen Kontext zur Antikoagulation bietet und keine Unterstützung für die Blutegeltherapie liefert.
Zitation
Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis.
Sirico et al. · The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2019
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026